Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405687 | 1.00 | GLP1R (0.60) | GLP1R | |
| SCHEMBL24276782 | 1.00 | GLP1R (0.60) | GLP1R | |
| SCHEMBL24276750 | 0.95 | GLP1R (0.54) | GLP1R | |
| SCHEMBL29406888 | 0.95 | GLP1R (0.54) | GLP1R | |
| SCHEMBL24277198 | 0.95 | GLP1R (0.54) | GLP1R | |
| SCHEMBL26185737 | 0.95 | GLP1R (0.54) | GLP1R | |
| SCHEMBL30461937 | 0.95 | GLP1R (0.62) | GLP1R | |
| SCHEMBL26185735 | 0.95 | GLP1R (0.62) | GLP1R | |
| SCHEMBL24277746 | 0.95 | GLP1R (0.62) | GLP1R | |
| SCHEMBL27101579 | 0.95 | GLP1R (0.62) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2022052958-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.